Key factors
sym | 0KCC |
exch | LSE |
MCap | 226.73M |
Beta | 0.778 |
EPS | -0.77 |
Div date | 0000-00-00 |
Yesterday
sym | 0KCC |
exch | LSE |
close | 2.5 |
50 Day MA | 1.768 |
200 Day MA | 1.768 |
52 Week High | 5.6 |
52 Week Low | 2.315 |
Market Cap Mln | 226.73 |
Share statistics
Shares Outstanding | 40.66M |
Shares Float | 84385 |
Percent Institutions | 86.15 |
PercentInsiders | 20.64 |
Income
Revenue TTM | 1503.0K |
Revenue Per Share TTM | 0.196 |
Quarterly Revenue Growth YOY | 14.59 |
Gross Profit TTM | 188.0K |
EBITDA | -20.5M |
Diluted Eps TTM | -0.77 |
earning
Operating Margin TTM | -16.1 |
Earnings Share | -0.77 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2023-07-25 |
Last Split Factor | 0.05:1 |
business
Book Value /share | 2.478 |
Price Sales TTM | 3.005 |
ReturnOnAssetsTTM | -0.15 |
ReturnOnEquityTTM | -0.76 |
Sector
Gic Group | Commercial & Professional Services |
Gic Industry | Commercial Services & Supplies |
Gic Sector | Industrials |
Gic Sub Industry | Environmental & Facilities Services |
Codes
Code | 0KCC |
CountryISO | GB |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | LSE |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-26 |
info
Fiscal Year End | December |
Full Time Employees | 43.0 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Oncocyte Corp. |
Address | 15 Cushing, Irvine, CA, United States, 92618 |
Country Name | UK |
Phone | 949 409 7600 |
Web URL | https://oncocyte.com |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.